Biotech Values

[ariadndndough]

ponatinib --- medium time still not reached on these patients wonderful news and great drug.



“These results reaffirm sustained durable responses to ponatinib with median time on ponatinib treatment still not reached among chronic-phase patients, as well as response rates that are remarkable in this refractory patient population,“ said Frank G. Haluska, M.D., Ph.D., vice president and chief medical officer of ARIAD.“Importantly, the data show no new significant safety findings on ponatinib and provide further evidence that ponatinib continues to be well tolerated across therapeutic dose levels including at the 45 mg dose being studied in the pivotal PACE trial,” added Dr. Haluska.